ArticleHepatology communications2019
Medication-Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention.
Article in Hepatology communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 48 citations in OpenAlex.
- Effectiveness of patient-oriented education and medication management intervention in people with decompensated cirrhosis.Internal medicine journal · 2020Trial
- Thirst in End-Stage Liver Disease: From Symptom Disregard to a Multidisciplinary Clinical Pathway and Future Perspectives: A Narrative Review.Journal of multidisciplinary healthcare · 2026Review
- Medication safety in patients with hepatic disease: proof of concept of a new approach to screen for patients at risk-a retrospective evaluation utilizing electronic prescribing systems.International journal of clinical pharmacy · 2025Article
- Prevalence of Polypharmacy Among Patients with Chronic Liver Disease-A Narrative Literature Review.Journal of clinical medicine · 2025Review
- Exploring the suitability of a ward-based clinical pharmacy activity collection tool for ambulatory care practice: a mixed-methods study.International journal of clinical pharmacy · 2025Article
- Changing Prevalence of Medication Use in People with Cirrhosis: A Retrospective Cohort Study Using Pharmaceutical Benefits Scheme Data.Drugs - real world outcomes · 2023Article
- Comparison of Drug-Related Problems in COVID-19 and Non-COVID-19 Patients Provided by a German Telepharmacy Service for Rural Intensive Care Units.Journal of clinical medicine · 2023Article
- Identifying opportunities for hepatic encephalopathy self-management: A mixed methods systematic review and synthesis.Canadian liver journal · 2023Article
- Poor disease knowledge is associated with higher healthcare service use and costs among patients with cirrhosis: an exploratory study.BMC gastroenterology · 2022Article
- Management of Pharmacologic Adverse Effects in Advanced Liver Disease.Clinical drug investigation · 2022Review
- Benefits, challenges and contributors to the introduction of new hospital-based outpatient clinic pharmacist positions.Exploratory research in clinical and social pharmacy · 2022Article
- Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?Frontiers in medicine · 2022Review
- Medication Discrepancies and Regimen Complexity in Decompensated Cirrhosis: Implications for Medication Safety.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Appropriate and Potentially Inappropriate Medication Use in Decompensated Cirrhosis.Hepatology (Baltimore, Md.) · 2021Article
- Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM.BMJ open gastroenterology · 2021Article
- Medication-Related Problems in Liver Transplant Recipients in the Outpatient Setting: A Dutch Cohort Study.Frontiers in pharmacology · 2021Article
- Improving Medication-Related Outcomes in Chronic Liver Disease.Hepatology communications · 2020Review
- ICD-10-AM codes for cirrhosis and related complications: key performance considerations for population and healthcare studies.BMJ open gastroenterology · 2020Article
- Medication safety in patients with hepatic impairment: A survey of community pharmacists' knowledge level and their practice in caring for these patients.British journal of clinical pharmacology · 2020Article
- Adherence to Oral Nutritional Supplements After Being Discharged from the Hospital is Low but Improves Outcome in Patients with Advanced Chronic Liver Disease.Patient preference and adherence · 2020Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
People with decompensated cirrhosis are often prescribed a complex regimen of therapeutic and prophylactic medications. In other chronic diseases, polypharmacy increases the risk of medication misadventure and medication-related problems (MRPs), with associated increased morbidity, mortality, and health care costs. This study examined MRPs in a cohort of ambulatory patients with a history of decompensated cirrhosis who were enrolled in a randomized controlled trial of a pharmacist-led, patient-oriented medication education intervention and assessed the association between MRPs and patient outcomes. A total of 375 MRPs were identified among 57 intervention patients (median, 6.0; interquartile range, 3.5-8.0 per patient; maximum 17). Nonadherence (31.5%) and indication issues (29.1%) were the most prevalent MRP types. The risk of potential harm associated with MRPs was low in 18.9% of instances, medium in 33.1%, and high in 48.0%, as categorized by a clinician panel using a risk matrix tool. Patients had a greater incidence rate of high-risk MRPs if they had a higher Child-Pugh score (incidence rate ratio [IRR], 1.31; 95% confidence interval [CI], 1.09-1.56); greater comorbidity burden (IRR, 1.15; 95% CI, 1.02-1.29); and were taking more medications (IRR, 1.12; 95% CI, 1.04-1.22). A total of 221 MRPs (58.9%) were resolved following pharmacist intervention. A greater proportion of high-risk MRPs were resolved compared to those of low and medium risk (68.9% versus 49.7%;
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.